Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)
NCT ID: NCT04490837
Last Updated: 2021-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3500 participants
OBSERVATIONAL
2020-06-22
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Contact Study by Antigen Detection Test
NCT04745533
Differential Leucocyte Count and Covid-19 Diagnosis
NCT04643860
Rapid Detection of COVID-19 by Portable and Connected Biosensor
NCT04367142
Dynamic Evaluation of COVID-19 Diagnostic Tests
NCT04337996
Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19)
NCT04425759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 positive
Patients with clinical, radiological and/or PCR positive for COVID-19 infection
ELISA and Rapid test to detect antibodies against COVID-19
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
Normal
Normal human serum from blood donnors before COVID-19 pandemia
ELISA and Rapid test to detect antibodies against COVID-19
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
Pathological controls
Patients with other positive virological serologies
ELISA and Rapid test to detect antibodies against COVID-19
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELISA and Rapid test to detect antibodies against COVID-19
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with clinical, radiological and/or PCR COVID-19 positive
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Corporacion Parc Tauli
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juan Francisco Delgado de la Poza
Senior Medical Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parc Tauli University Hospital
Sabadell, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020/587
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.